지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학위논문
- 저자정보
- 지도교수
- 이영
- 발행연도
- 2016
- 저작권
- 충남대학교 논문은 저작권에 의해 보호받습니다.
이용수2
이 논문의 연구 히스토리 (2)
- 이 논문의 후속연구가 궁금하신가요?
- 연관 학술논문 또는 학술발표를 통해 보다 발전된 연구결과를 확인하실 수 있습니다.
- 이 논문의 연구 히스토리 확인하기
초록· 키워드
오류제보하기
Background:Alopecia areata (AA) is an autoimmune skin disease that is difficult to manage and treat. The pathogenesis of AA features a T-cell-associated autoimmune process, and systemic immunosuppressive therapies are thus widely prescribed. Methotrexate (MTX) is a folic acid antagonist used in the treatment of inflammatory skin diseases such as psoriasis and atopic dermatitis. However, MTX is seldom used to treat AA. A weekly dose of 7.5?20 mg MTX is termed low-dose methotrexate (LD-MTX), and is a treatment option for AA.
Objectives:To evaluate the efficacy of systemic LD-MTX therapy in AA patients.
Methods: We conducted a retrospective study on patients with AA treated with LD-MTX from January 2008 to August 2015 in our clinic.
Results:A total of 30 patients (16 males and 14 females) aged between 16 and 65 years (mean, 40.23 years) were included. Treatment was administered twice weekly, and the mean maximal dose was 14.3 mg weekly (range:10?17.5 mg). Excellent response (regrowth >50%) was observed in 15 (50%) patients, and good response (regrowth of 25?50%) in 12 (40%). Three patients (10%) exhibited poor response (regrowth < 25%). Common side-effects were elevation of liver enzyme levels (10%) and gastrointestinal discomfort (10%).
Conclusions:This study suggests that LD-MTX may be an effective treatment option for AA.
Objectives:To evaluate the efficacy of systemic LD-MTX therapy in AA patients.
Methods: We conducted a retrospective study on patients with AA treated with LD-MTX from January 2008 to August 2015 in our clinic.
Results:A total of 30 patients (16 males and 14 females) aged between 16 and 65 years (mean, 40.23 years) were included. Treatment was administered twice weekly, and the mean maximal dose was 14.3 mg weekly (range:10?17.5 mg). Excellent response (regrowth >50%) was observed in 15 (50%) patients, and good response (regrowth of 25?50%) in 12 (40%). Three patients (10%) exhibited poor response (regrowth < 25%). Common side-effects were elevation of liver enzyme levels (10%) and gastrointestinal discomfort (10%).
Conclusions:This study suggests that LD-MTX may be an effective treatment option for AA.
목차
ABSTRACT 5I. INTRODUCTION 7II. MATERIAL AND METHODS 9III. RESULTS 11IV. DISCUSSION 13V. TABLE&FIGURES 17VI. REFERENCE 21VII. ABSTRACT IN KOREAN 25
최근 본 자료
댓글(0)
0